GlaxoSmithKline plc (NYSE:GSK) – Research analysts at Jefferies Financial Group increased their FY2019 EPS estimates for shares of GlaxoSmithKline in a research note issued on Wednesday, July 10th. Jefferies Financial Group analyst P. Welford now expects that the pharmaceutical company will post earnings per share of $2.94 for the year, up from their previous forecast of $2.91. Jefferies Financial Group also issued estimates for GlaxoSmithKline’s Q4 2019 earnings at $0.74 EPS, FY2020 earnings at $3.11 EPS, FY2021 earnings at $3.55 EPS and FY2022 earnings at $3.80 EPS.
A number of other equities research analysts have also recently commented on GSK. Morgan Stanley assumed coverage on in a research note on Monday, June 17th. They issued an “equal weight” rating and a GBX 215 ($2.81) target price on the stock. Zacks Investment Research raised Green Brick Partners from a “sell” rating to a “hold” rating in a research report on Thursday, April 25th. Finally, Cowen reaffirmed a “buy” rating on shares of Aptinyx in a research report on Monday, June 10th. One research analyst has rated the stock with a sell rating, sixteen have issued a hold rating and three have given a buy rating to the stock. GlaxoSmithKline presently has an average rating of “Hold” and a consensus price target of $42.28.
GlaxoSmithKline (NYSE:GSK) last released its earnings results on Wednesday, May 1st. The pharmaceutical company reported $0.79 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.13. GlaxoSmithKline had a return on equity of 157.04% and a net margin of 12.27%. The firm had revenue of $9.98 billion for the quarter, compared to analysts’ expectations of $9.86 billion.
The company also recently announced a quarterly dividend, which was paid on Thursday, July 11th. Shareholders of record on Friday, May 17th were issued a $0.4953 dividend. This represents a $1.98 dividend on an annualized basis and a yield of 4.90%. The ex-dividend date of this dividend was Thursday, May 16th. GlaxoSmithKline’s dividend payout ratio is 58.86%.
In other news, Director Plc Glaxosmithkline bought 325,000 shares of the stock in a transaction on Monday, April 22nd. The shares were bought at an average price of $18.00 per share, with a total value of $5,850,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders acquired 1,044,047 shares of company stock worth $16,249,991. 10.00% of the stock is owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of GSK. Norges Bank bought a new position in shares of GlaxoSmithKline in the fourth quarter worth about $17,275,000. Two Sigma Investments LP bought a new stake in GlaxoSmithKline during the 4th quarter valued at approximately $15,936,000. Deutsche Bank AG raised its stake in GlaxoSmithKline by 221.0% during the 4th quarter. Deutsche Bank AG now owns 529,309 shares of the pharmaceutical company’s stock valued at $20,222,000 after purchasing an additional 364,431 shares during the period. Millennium Management LLC raised its stake in GlaxoSmithKline by 612.0% during the 4th quarter. Millennium Management LLC now owns 365,325 shares of the pharmaceutical company’s stock valued at $13,959,000 after purchasing an additional 314,016 shares during the period. Finally, Foundry Partners LLC bought a new stake in GlaxoSmithKline during the 1st quarter valued at approximately $6,917,000. 11.26% of the stock is currently owned by institutional investors.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Read More: What is the outlook for the FAANG stocks?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.